Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
DIAGNOSTIC_TEST

Iohexol measurement

Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.

DRUG

Geranylgeranylacetone (GGA)

13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.

DIAGNOSTIC_TEST

Echocardiography

The investigators will perform echocardiography to find changes in cardiac function.

DIAGNOSTIC_TEST

6-minute walking distance test

6 minute walking distance test to compare exercise tolerance in participants.

DIAGNOSTIC_TEST

EndoPAT

Use of EndoPAT to measure endothelial function.

DIAGNOSTIC_TEST

Para-amino Hippuric Acid test

PAH-measurement to measure ERPF.

DIAGNOSTIC_TEST

Electrocardiogram

12-lead Electrocardiogram

Trial Locations (1)

Unknown

Amsterdam UMC, loc VUmc, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER